Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant ...

New Study from Society of Actuaries Research Institute Dives into Trends and Drivers of Substance-Related Mortality in the U.S.

Support Survey Explores Public Awareness of Drug and Alcohol UseCHICAGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- A study by the ...